Withuspharmaceutical Co.Ltd
WITHUS PHARMACEUTICAL Co.,LTD. engages in the production and sale of pharmaceutical products in South Korea. It offers circulatory agents, endocrine cost medications, osteoporosis treatment products, antithrombotic medicines, central nervous system agents, digestive tract medications, respiratory/skin preparations, musculoskeletal medications, antibiotics, antifungal and antiviral drugs, genitour… Read more
Withuspharmaceutical Co.Ltd (330350) - Total Liabilities
Latest total liabilities as of September 2025: ₩42.70 Billion KRW
Based on the latest financial reports, Withuspharmaceutical Co.Ltd (330350) has total liabilities worth ₩42.70 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Withuspharmaceutical Co.Ltd - Total Liabilities Trend (2017–2024)
This chart illustrates how Withuspharmaceutical Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Withuspharmaceutical Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Withuspharmaceutical Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mcleod Russel India Limited
NSE:MCLEODRUSS
|
India | ₹36.93 Billion |
|
Master Tec Group Berhad
KLSE:0295
|
Malaysia | RM94.06 Million |
|
Birikim Varlik Yonetim A.S.
IS:BRKVY
|
Turkey | TL1.22 Billion |
|
Hong Ho Precision Textile Co Ltd
TW:1446
|
Taiwan | NT$373.09 Million |
|
BATI EGE GMYO
IS:BEGYO
|
Turkey | TL49.55 Million |
|
Mahachai Hospital Public Company Limited
BK:M-CHAI
|
Thailand | ฿7.98 Billion |
|
Sensys Gatso Group AB
ST:SGG
|
Sweden | Skr534.85 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Withuspharmaceutical Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Withuspharmaceutical Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Withuspharmaceutical Co.Ltd (2017–2024)
The table below shows the annual total liabilities of Withuspharmaceutical Co.Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩41.57 Billion | +2.64% |
| 2023-12-31 | ₩40.50 Billion | +11.40% |
| 2022-12-31 | ₩36.36 Billion | -4.50% |
| 2021-12-31 | ₩38.07 Billion | +29.93% |
| 2020-12-31 | ₩29.30 Billion | -3.14% |
| 2019-12-31 | ₩30.25 Billion | +26.83% |
| 2018-12-31 | ₩23.85 Billion | -4.29% |
| 2017-12-31 | ₩24.92 Billion | -- |